Aromatase inhibitors
- Block estrogen synthesis
- Core endocrine therapy after menopause
- anastrozole, letrozole, exemestane
- HR-positive breast cancer is the major use
- Arthralgia + hot flashes are common
- Bone loss/fracture risk exceeds tamoxifen
- No tamoxifen-like VTE/endometrial risk
Class at a glance
Practical pearls
- Core endocrine therapy after menopause
- anastrozole, letrozole, exemestane
Clinical role
- HR-positive breast cancer is the major use
- Arthralgia + hot flashes are common
Safety / monitoring
- Bone loss/fracture risk exceeds tamoxifen
- No tamoxifen-like VTE/endometrial risk
Self-check
- What is the main pharmacologic action of Aromatase inhibitors?
Block estrogen synthesis.
Drugs in this class (3)
All drug classes · Open the interactive console ↗
